Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2014 | 2 |
2019 | 1 |
2020 | 1 |
2021 | 3 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
Alzheimers Dement. 2021 Aug;17(8):1365-1382. doi: 10.1002/alz.12302. Epub 2021 Feb 8.
Alzheimers Dement. 2021.
PMID: 33559354
Free PMC article.
Clinical Trial.
Sigma-2 receptor antagonists rescue neuronal dysfunction induced by Parkinson's patient brain-derived α-synuclein.
Limegrover CS, Yurko R, Izzo NJ, LaBarbera KM, Rehak C, Look G, Rishton G, Safferstein H, Catalano SM.
Limegrover CS, et al. Among authors: safferstein h.
J Neurosci Res. 2021 Apr;99(4):1161-1176. doi: 10.1002/jnr.24782. Epub 2021 Jan 22.
J Neurosci Res. 2021.
PMID: 33480104
Free PMC article.
Item in Clipboard
Alzheimer's protection effect of A673T mutation may be driven by lower Aβ oligomer binding affinity.
Limegrover CS, LeVine H 3rd, Izzo NJ, Yurko R, Mozzoni K, Rehak C, Sadlek K, Safferstein H, Catalano SM.
Limegrover CS, et al. Among authors: safferstein h.
J Neurochem. 2021 May;157(4):1316-1330. doi: 10.1111/jnc.15212. Epub 2020 Oct 25.
J Neurochem. 2021.
PMID: 33025581
Free PMC article.
Item in Clipboard
A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease.
Grundman M, Morgan R, Lickliter JD, Schneider LS, DeKosky S, Izzo NJ, Guttendorf R, Higgin M, Pribyl J, Mozzoni K, Safferstein H, Catalano SM.
Grundman M, et al. Among authors: safferstein h.
Alzheimers Dement (N Y). 2019 Jan 23;5:20-26. doi: 10.1016/j.trci.2018.11.001. eCollection 2019.
Alzheimers Dement (N Y). 2019.
PMID: 30723776
Free PMC article.
Item in Clipboard
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H 3rd, Spires-Jones TL, Catalano SM.
Izzo NJ, et al. Among authors: safferstein h.
PLoS One. 2014 Nov 12;9(11):e111899. doi: 10.1371/journal.pone.0111899. eCollection 2014.
PLoS One. 2014.
PMID: 25390692
Free PMC article.
Item in Clipboard
Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Catalano SM.
Izzo NJ, et al. Among authors: safferstein h.
PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. eCollection 2014.
PLoS One. 2014.
PMID: 25390368
Free PMC article.
Item in Clipboard
Cite
Cite